2. Cell Cycle/DNA Damage Anti-infection
  3. Nucleoside Antimetabolite/Analog HSV Parasite
  4. SIBA

SIBA  (Synonyms: 5'-Isobutylthioadenosine; 5'-Deoxy-5'-isobutylthioadenosine)

Cat. No.: HY-18684 Purity: 99.64%
COA Handling Instructions

Molarity Calculator

SIBA (5'-Isobutylthioadenosine) is a transmethylation inhibitor (SAH (HY-19528) analogue), with potent anti-proliferative activity. SIBA reversibly inhibits the production of HSV-1 by blocking methylation, specifically by blocking the 5' end-capping of viral mRNA. SIBA also inhibits the growth of tumour cells in vitro and metastatic spread in vivo. SIBA can be used in cancer, HSV-1 infection and anti-malaria studies.

For research use only. We do not sell to patients.

SIBA Chemical Structure

SIBA Chemical Structure

CAS No. : 35899-54-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 215 In-stock
Solution
10 mM * 1 mL in DMSO USD 215 In-stock
Solid
1 mg USD 93 In-stock
5 mg USD 195 In-stock
10 mg USD 255 In-stock
50 mg USD 765 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

SIBA Related Antibodies

Top Publications Citing Use of Products

View All HSV Isoform Specific Products:

View All Isoforms
HSV-1 HSV-2 HSV

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SIBA (5'-Isobutylthioadenosine) is a transmethylation inhibitor (SAH (HY-19528) analogue), with potent anti-proliferative activity. SIBA reversibly inhibits the production of HSV-1 by blocking methylation, specifically by blocking the 5' end-capping of viral mRNA. SIBA also inhibits the growth of tumour cells in vitro and metastatic spread in vivo. SIBA can be used in cancer, HSV-1 infection and anti-malaria studies[1][2][3].

IC50 & Target[2]

Plasmodium

 

HSV-1

 

In Vitro

SIBA (0.5 mM; 24-96 h) shows strong anti-proliferative activity against 3LL and RMS-J1 tumour cells[1].
SIBA (1 mM; 12, 24 h) reversibly inhibits HSV production in HEp2 cells (infected by HSV-1)[2].
SIBA inhibits protein synthesis by 98% after 10 h infection of HEp2 cells (infected by HSV-1)[2].
SIBA (1 mM; 8.5 h) inhibits protein synthesis and RNA methylation in HEp2 cells (infected by HSV-1)[2].
SIBA (0.5, 1.0 mM; 24, 48 h) inhibits the conversion of putrescine into spermidine and/or spermine and that this inhibition is a reversible one (interferes with polyamine biosynthesis, probably by blocking aminopropyltransferase)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SIBA Related Antibodies

Cell Proliferation Assay[1]

Cell Line: 3 LL and RMS-J1 cells
Concentration: 0.5 mM
Incubation Time: 24-96 h
Result: Inhibited 3LL and RMS-J1 tumor cell growth potently by 96% and 88%, respectively.

Cell Viability Assay[2]

Cell Line: HEp2 cells (infected by HSV-1)
Concentration: 1 mM
Incubation Time: 12, 24 h
Result: Decreased virus production by 88.4 and 98.2% when at 12 and 24 h, respectively.

Cell Viability Assay[2]

Cell Line: HEp2 cells (infected by HSV-1)
Concentration: 1 mM
Incubation Time: 8.5 h
Result: Reduced protein synthesis by 41.3% in normal medium and by 63.5% in medium poor in methionine.
Inhibited RNA methylation by 65.4%.

Cell Viability Assay[3]

Cell Line: chick embryo fibroblasts
Concentration: 0.5, 1.0 mM
Incubation Time: 24, 48 h
Result: Inhibited the uptake of the radioactive diamine and that the inhibition was dose-dependent.
Markedly inhibited the formation of [14C]spermidine and [14C]spermine from [14C]putrescine.
Inhibited the growth of chick embryo fibroblasts mainly after exposure for 48 h.
In Vivo

SIBA (150 mg/kg; i.p.; twice weekly for 3 weeks) inhibits tumor growth in vivo[1].
SIBA (15 mg/kg; i.p.; thrice weekly for 4 weeks) inhibits metastatic spread of RMS-J1 cells in vivo[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 female mice (4-8 weeks old)[1].
Dosage: 150 mg/kg
Administration: Intraperitoneal injection; twice weekly for 3 weeks.
Result: Significantly reduced the median number of lung metastases.
Animal Model: Adult syngeneic Wistar AG rats (8-week-old; subcutaneously grafted with RMS-J1 cells)[1].
Dosage: 15 mg/kg
Administration: Intraperitoneal injection; thrice weekly for 4 weeks.
Result: Inhibited in vivo metastatic spread of RMS-J1 cells, and showed median numbers of lung metastatic nodules was 26.
Molecular Weight

339.41

Formula

C14H21N5O3S
CAS No.
Appearance

Solid

Color

Off-white to gray

SMILES

O[C@@H]([C@H]([C@H](N1C=NC2=C1N=CN=C2N)O3)O)[C@H]3CSCC(C)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (294.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9463 mL 14.7314 mL 29.4629 mL
5 mM 0.5893 mL 2.9463 mL 5.8926 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.9463 mL 14.7314 mL 29.4629 mL 73.6572 mL
5 mM 0.5893 mL 2.9463 mL 5.8926 mL 14.7314 mL
10 mM 0.2946 mL 1.4731 mL 2.9463 mL 7.3657 mL
15 mM 0.1964 mL 0.9821 mL 1.9642 mL 4.9105 mL
20 mM 0.1473 mL 0.7366 mL 1.4731 mL 3.6829 mL
25 mM 0.1179 mL 0.5893 mL 1.1785 mL 2.9463 mL
30 mM 0.0982 mL 0.4910 mL 0.9821 mL 2.4552 mL
40 mM 0.0737 mL 0.3683 mL 0.7366 mL 1.8414 mL
50 mM 0.0589 mL 0.2946 mL 0.5893 mL 1.4731 mL
60 mM 0.0491 mL 0.2455 mL 0.4910 mL 1.2276 mL
80 mM 0.0368 mL 0.1841 mL 0.3683 mL 0.9207 mL
100 mM 0.0295 mL 0.1473 mL 0.2946 mL 0.7366 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SIBA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SIBA35899-54-85'-Isobutylthioadenosine 5'-Deoxy-5'-isobutylthioadenosineNucleoside Antimetabolite/AnalogHSVParasiteHerpes simplex virusHSV-1SAH3 LLRMS-J1HEp2cancermalariachick embryo fibroblastsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SIBA
Cat. No.:
HY-18684
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.